To register an innovative drug in Taiwan, applicants must submit a New Drug Application (NDA) with clinical trial data proving safety, efficacy, and quality, along with Good Manufacturing Practice (GMP) compliance documentation. The TFDA conducts thorough reviews, with the possibility of accelerated pathways for priority drugs addressing unmet medical needs.